Author:
Pukac L,Kanakaraj P,Humphreys R,Alderson R,Bloom M,Sung C,Riccobene T,Johnson R,Fiscella M,Mahoney A,Carrell J,Boyd E,Yao X T,Zhang L,Zhong L,von Kerczek A,Shepard L,Vaughan T,Edwards B,Dobson C,Salcedo T,Albert V
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K (2003) A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 88: 298–306
2. Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S, Blackie C, Chang L, McMurtrey A, Herbert A, DeForge L, Koumenis I, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokn Z, Schwall R (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155–162
3. Asakuma J, Sumitomo M, Asano T, Hayakawa M (2003) Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63: 1365–1370
4. Berger M, Shankar V, Vafai A (2002) Therapeutic applications of monoclonal antibodies. Am J Med Sci 324: 14–30
5. Bouralexis S, Evdokiou A, Hay S, Atkins G, Findlay D (2001) Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: a potential new approach using TRAIL. J Orthop Surg 9: 19–22
Cited by
274 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献